Open AccessComparison of losartan and amlodipine effects on the outcomes of patient with COVID‐19 and primary hypertension: A randomised clinical trial
Author(s) -
NouriVaskeh Masoud,
Kalami Niusha,
Zand Ramin,
Soroureddin Zahra,
Varshochi Mojtaba,
Ansarin Khalil,
Rezaee Haleh,
Taghizadieh Ali,
Sadeghi Armin,
Ahangari Maleki Masoud,
Esmailnajad Azam,
Saleh Parviz,
Haghdoost Mehdi,
Maleki Mehdi,
Sharifi Akbar
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.14124
Subject(s) - medicine , losartan , amlodipine , randomized controlled trial , clinical trial , blood pressure , angiotensin ii
Background Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID‐19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID‐19. Methods In this randomised clinical trial, hospitalised patients with COVID‐19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30‐day mortality rate and length of hospital stay. Results The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively ( P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively ( P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively ( P value = .994). The 30‐day mortality was two and five patients in losartan and amlodipine groups, respectively ( P value = .241). Conclusions There was no priority in losartan or amlodipine administration in COVID‐19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first‐line anti‐HTN medications in COVID‐19.